Reclaimed at end of life
Tonnes as filed. Totals combine re-used, recycled and safely disposed, because filers place comparable activity in different columns.
reporting_boundary_changed. Reporting boundary changed across years: FY 2022-23 Standalone basis, FY 2023-24 Consolidated, FY 2024-25 Consolidated. Year-on-year figures cover different entities.
| Category | FY 2022-23 | FY 2023-24 | FY 2024-25 |
|---|---|---|---|
| Plastics including packaging | not filed | 0 | 0 |
| E-waste | not filed | 0 | 0 |
| Hazardous waste | not filed | 0 | 0 |
| Other waste | not filed | not filed | not filed |
| Total reclaimed | 0 | 0 | 0 |
Recycled or reused input material
Share of total material by value, per material line as the company named it. Each line carries its own denominator, so they are never summed or averaged.
| Input material, as filed | FY 2022-23 | FY 2023-24 | FY 2024-25 |
|---|---|---|---|
| We are into pharmaceutical industry, strictly regulated by provisions regulating our manufacturing processes & usage of inputs material for manufacture of APIs & formulations, which does not allow us to use any reused/ recycled inputs material. | 0.0% | not filed | not filed |
NIC codes filed
Products and services accounting for 90 percent of turnover, latest filing.
| Code | Description as filed | Share of turnover |
|---|---|---|
| 21005 | Albendazole | 30.00% |
| 21005 | Triclabendazole | 11.00% |
| 21005 | Clorsulon | 4.00% |
| 21005 | Others | 55.00% |
Source filings
| Year | Basis | Taxonomy | Turnover as filed |
|---|---|---|---|
| FY 2022-23 | Standalone basis | 2023-06-30 | 2,22,68,50,000 |
| FY 2023-24 | Consolidated | 2024-04-30 | 1,68,51,80,000 |
| FY 2024-25 | Consolidated | 2025-05-31 | 0 |
Figures read from BRSR XBRL as filed. Nothing estimated or restated. How this works · Report an error